4591.T
RIBOMIC Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 83.00
−5.68%Year over year
Reported trailing growth
- Revenue
- -97.7%
- EBITDA
- —
- EBIT
- -0.1%
- EPS
- +9.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +50.0%
- EBITDA
- —
- EPS
- -10.0%
Three-year CAGR
- Revenue
- -70.8%
- EBITDA
- +5.1%
- EBIT
- +5.9%
- Net income
- +0.6%
- EPS
- +12.2%
- Free cash flow
- -7.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026